MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $228.05 million. The enterprise value is $89.83 million.
| Market Cap | 228.05M |
| Enterprise Value | 89.83M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 63.70 million shares outstanding. The number of shares has increased by 0.77% in one year.
| Current Share Class | 63.70M |
| Shares Outstanding | 63.70M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 3.58% |
| Owned by Institutions (%) | 70.81% |
| Float | 56.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.30 |
| Forward PS | 2.67 |
| PB Ratio | 5.31 |
| P/TBV Ratio | 5.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.96, with a Debt / Equity ratio of 0.82.
| Current Ratio | 2.96 |
| Quick Ratio | 2.92 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.25 |
Financial Efficiency
Return on equity (ROE) is -225.85% and return on invested capital (ROIC) is -29.40%.
| Return on Equity (ROE) | -225.85% |
| Return on Assets (ROA) | -8.05% |
| Return on Invested Capital (ROIC) | -29.40% |
| Return on Capital Employed (ROCE) | -16.09% |
| Weighted Average Cost of Capital (WACC) | 14.50% |
| Revenue Per Employee | $597,754 |
| Profits Per Employee | -$49,802 |
| Employee Count | 293 |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -777,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +110.59% in the last 52 weeks. The beta is 1.21, so MacroGenics's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | +110.59% |
| 50-Day Moving Average | 4.00 |
| 200-Day Moving Average | 3.27 |
| Relative Strength Index (RSI) | 38.37 |
| Average Volume (20 Days) | 589,528 |
Short Selling Information
The latest short interest is 7.03 million, so 11.04% of the outstanding shares have been sold short.
| Short Interest | 7.03M |
| Short Previous Month | 7.12M |
| Short % of Shares Out | 11.04% |
| Short % of Float | 12.47% |
| Short Ratio (days to cover) | 16.17 |
Income Statement
In the last 12 months, MacroGenics had revenue of $175.14 million and -$14.59 million in losses. Loss per share was -$0.23.
| Revenue | 175.14M |
| Gross Profit | -1.30M |
| Operating Income | -38.06M |
| Pretax Income | -101.83M |
| Net Income | -14.59M |
| EBITDA | -32.17M |
| EBIT | -38.06M |
| Loss Per Share | -$0.23 |
Balance Sheet
The company has $173.31 million in cash and $35.09 million in debt, with a net cash position of $138.21 million or $2.17 per share.
| Cash & Cash Equivalents | 173.31M |
| Total Debt | 35.09M |
| Net Cash | 138.21M |
| Net Cash Per Share | $2.17 |
| Equity (Book Value) | 42.87M |
| Book Value Per Share | 0.67 |
| Working Capital | 212.87M |
Cash Flow
In the last 12 months, operating cash flow was -$63.72 million and capital expenditures -$1.82 million, giving a free cash flow of -$65.54 million.
| Operating Cash Flow | -63.72M |
| Capital Expenditures | -1.82M |
| Depreciation & Amortization | 5.89M |
| Net Borrowing | n/a |
| Free Cash Flow | -65.54M |
| FCF Per Share | -$1.03 |
Margins
Gross margin is -0.74%, with operating and profit margins of -21.73% and -8.33%.
| Gross Margin | -0.74% |
| Operating Margin | -21.73% |
| Pretax Margin | -58.14% |
| Profit Margin | -8.33% |
| EBITDA Margin | -18.37% |
| EBIT Margin | -21.73% |
| FCF Margin | n/a |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.77% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.40% |
| FCF Yield | -28.74% |
Analyst Forecast
The average price target for MacroGenics is $8.00, which is 123.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 123.46% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -15.52% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -3.95 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.95 |
| Piotroski F-Score | 1 |